Doxycycline, Temozolomide and Ipilimumab in Melanoma
Summary
The goal of this clinical research study is to find the highest tolerable dose of doxycycline that can be combined with temozolomide and ipilimumab in patients with advanced melanoma. The safety and level of effectiveness of the study drug combination will also be studied. Doxycycline is designed to treat bacterial infection. It also blocks a protein called iNOS that is important in tumor cell growth, which may slow the growth of or kill cancer cells. Temozolomide is designed to stop cancer cells from making new DNA (the genetic material of cells). This may stop the cancer cells from dividing into new cells. Ipilimumab is designed to block the activity of cells that decrease the immune system's ability to fight cancer.
Timeline
- Start
- 2012-11
- Primary completion
- 2015-07
- Completion
- 2015-07
Outcome
Outcome not reported
Stopped (Enrollment): “Accrual slow due to alternate trials and treatment options.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxycycline | Small molecule | 200 mg | Oral |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg | Intravenous |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |